| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Profit before tax | -19.9 | -5.5 |
| Net income | -19.9 | -5.5 |
| EPS (diluted, $ a share) | $-0.01 | $-0.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, OTC: CYDY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
CytoDyn Inc.: key numbers
- Share price
- $0.2502Close, Nov 16
- Market cap
- $368M
- Shares outstanding
- 1.47BLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from CytoDyn Inc.
All →CytoDyn Leadership Change
CytoDyn appointed Robert E. Hoffman as Chief Executive Officer, effective October 20, 2026, succeeding Dr. Jacob Lalezari. Dr. Lalezari resigned from the CEO role but will remain with the company as Head of Research and Translational Sciences. Mr. Hoffman, who previously served as the company's CFO, will also continue to serve as the principal accounting officer.